Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Medical Oncology (Northwood, London, England)|May 28, 2016
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?Pedro Cabrales, Jan Scicinski, Tony Reid, et al.Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.Discovery Medicine|April 27, 2016
Rockets, radiosensitizers, and RRx-001: an origin story part IBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.Investigational New Drugs|February 5, 2016
RRx-001, A novel dinitroazetidine radiosensitizerBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.Expert Opinion on Therapeutic Targets|April 2, 2020
TGF-beta: a master immune regulatorChristopher Larson, Bryan Oronsky, Corey A Carter, et al.Journal of Cancer Research and Clinical Oncology|April 19, 2017
RRx-001 protects against cisplatin-induced toxicitiesBryan Oronsky, Tony R Reid, Christopher Larson, et al.Neoplasia (New York, N.Y.)|December 12, 2017
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A ReviewBryan Oronsky, Patrick Ma, Tony R Reid, et al.Cancer Chemotherapy and Pharmacology|July 22, 2017
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and managementBryan Oronsky, Scott Caroen, Arnold Oronsky, et al.Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.Pageof 4